Details:
Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.
Lead Product(s): Abiraterone Acetate,Prednisolone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
Teriflunomide is a pyrimidine synthesis inhibitor with anti-inflammatory and immunomodulatory properties used to treat patients with the relapsing-remitting form of multiple sclerosis.
Lead Product(s): Teriflunomide
Therapeutic Area: Immunology Product Name: Teriflunomide-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.
Lead Product(s): Lacosamide
Therapeutic Area: Neurology Product Name: Lacosamide-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
The partnership aims to develop and commercialize products in the intersection between traditional drug-based medicine and digital therapeutics. Another novelty is to dispense the drugs as pellets instead of pills or capsules, making them easier to consume.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: OnDosis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration September 26, 2021
Details:
Bilastine is an innovative anti-allergy medicine improving the life of patients suffering from allergic symptoms also a second-generation antihistamine product helps to relieve nasal and non-nasal symptoms of seasonal rhinitis as well as urticaria caused symptoms.
Lead Product(s): Bilastine
Therapeutic Area: Immunology Product Name: Bilastine-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2021
Details:
Teriflunomide is a novel disease-modifying agent,primarily an inhibitor of dihydroorotate-dehydrogenase (DHODH), a key mitochondrial enzyme involved in the de novo synthesis of pyrimidines in rapidly proliferating cells.
Lead Product(s): Teriflunomide
Therapeutic Area: Immunology Product Name: Teriflunomide-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2021